Asymmetry Capital Management’s Avadel Pharmaceuticals AVDL Stock Holding History

Asymmetry Capital Management’s Portfolio AVDL Stock Details AVDL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	$2.98M	Sell	369,134 -105,234	-22%	-$962K	1.58%	20
2021 Q3	$4.65M	Buy	474,368 +74,592	+19%	+$587K	2.79%	18
2021 Q2	$2.69M	Sell	399,776 -312,595	-44%	-$2.48M	1.85%	20
2021 Q1	$6.44M	Sell	712,371 -243,485	-25%	-$1.97M	3.33%	15
2020 Q4	$6.38M	Buy	955,856 +435,026	+84%	+$2.72M	2.91%	14
2020 Q3	$2.63M	Sell	520,830 -12,802	-2%	-$93.1K	1.69%	23
2020 Q2	$4.31M	Buy	+533,632	New	+$4.7M	3.3%	12

Other funds holding AVDL

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

CAC

Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return

BIP

Brandes Investment Partners La Jolla, California $14.3B AUM 23.11% 1-Year Est. Return

GJL

Gendell Jeffrey L $11.3B AUM 163.06% 1-Year Est. Return

Wealth Effects Boston, Massachusetts $370M AUM 97.79% 1-Year Est. Return

Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return

Asymmetry Capital Management's AVDL Position: Q4 2021 in Review

Asymmetry Capital Management reduced its Avadel Pharmaceuticals (AVDL) stake by 22% in Q4 2021, selling an estimated $962K and leaving 369,134 shares worth $2.98M. The position accounts for 1.58% of the portfolio, ranked #20.

Asymmetry Capital Management first reported a position in AVDL in Q2 2020 and has held it in 7 quarters since. The position peaked at $6.44M in Q1 2021. 83 funds tracked by Wall St. Rank hold AVDL as of Q4 2021.

Asymmetry Capital Management held 369,134 shares of Avadel Pharmaceuticals worth $2.98M as of Q4 2021.
Asymmetry Capital Management sold 105,234 Avadel Pharmaceuticals shares in Q4 2021, an estimated $962K.
Avadel Pharmaceuticals made up 1.58% of Asymmetry Capital Management's portfolio in Q4 2021, its #20 holding.
Asymmetry Capital Management first reported a position in Avadel Pharmaceuticals in Q2 2020 and has held it in 7 quarters since.
Asymmetry Capital Management's Avadel Pharmaceuticals position peaked at $6.44M in Q1 2021.
83 funds tracked by Wall St. Rank held Avadel Pharmaceuticals as of Q4 2021.

Based on Asymmetry Capital Management's 13F filing for Q4 2021, filed 19 Jan 2022.